Compare Biogen Inc (BIIB) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Old Dominion Freight Line Inc — how do they compare? Biogen Inc trades at $206.74 (market cap $30.13B), while Old Dominion Freight Line Inc trades at $213.29 (market cap $43.43B). The key difference: Old Dominion Freight Line Inc is the larger of the two by market cap, and Old Dominion Freight Line Inc pays a 0.55% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ODFL | |
|---|---|---|
Market Cap | $30.13B | $43.43B |
Sector | Health | Industrials |
52-Week High | $216.63 | $248.73 |
52-Week Low | $128.93 | $126.29 |
Enterprise Value | $37.20B | $43.17B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
ODFL trades at $212.55, down 1.76% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 19.44% net margins and 24.82% ROE, though valuation metrics remain elevated with a P/E of 40.28. Recent Q2 2026 earnings of $1.68 per share exceeded expectations, driven by yield improvements and cost discipline amid ongoing freight market pressures.
The stock faces headwinds from premium valuation and mixed analyst sentiment (33% buy, 56% hold), but strong fundamentals and consistent earnings outperformance provide support. Key risks include freight volume recovery uncertainty and execution pressure given high expectations. The consensus price target of $239.85 suggests 13% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
